Century Therapeutics adds Joseph Truitt to board of directors
The iPSC-derived cell therapy company appointed the iECURE CEO effective September 9, 2026, expanding its board to seven members.
SEC filing
Latest
2 stories
Wednesday, September 9
Wednesday, August 12
Century Therapeutics reports Q2 2026 results, FDA pre-IND meeting for T1D program
Century says CNTY-813's IND submission is on track for the fourth quarter of 2026 after aligning with FDA on trial design, while cash on hand grew to $197.2 million.
SEC filing